// App-Quantinova.ai

: DuoResp Spiromax adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD (SPRINT)

Researchers

Presenter

  • Job van der Palen

Principal Investigators

  • Isa Cerveri

  • Nicolas Roche

  • Dave Singh

  • Vicente Plaza

  • Chelo Gonzalez

  • Oliver Patino

  • Irma Scheepstra

  • Guilherme Safioti

  • Vibeke Backer

Medical Centers

  • Department of Research Methodology, Measurement and Data Analysis, University of Twente. Medical School Twente, Medisch Spectrum Twente, Enschede, Netherlands

  • Unit of Respiratory Diseases, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy

  • Hôpitaux Universitaires Paris Centre, Cochin Hospital (APHP), University Paris Descartes (EA2511), Paris, France

  • Centre for Respiratory Medicine and Allergy, The University of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom

  • Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau. Institut d’Investigació Biomédica Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona. Department of Medicine, Barcelona, Spain

  • Unit of Statistics and Data Management, Experior SL, 46139 La Pobla de Farnals, Valencnia, Spain

  • Teva Pharmaceuticals, Amsterdam, Netherlands,

  • Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen University, Copenhagen, Denmark,

Locations

  • Netherlands

  • Italy

  • France

  • United Kingdom

  • Spain

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Asthma

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • DuoResp Spiromax

Outcome

  • N/A

Study Design

  • Fixed Dose

  • Observational

  • Multicenteric

Phase

  • IV

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved